This company operates_as a clinical - stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life - changing medicines for underserved patient populations suffering_from severe rare CAUSE_OF_DEATH and CAUSE_OF_DEATH. It was_founded in DATE conducts_business_from its_registered_head office_located in CITY,_STATE_OR_PROVINCE, COUNTRY COUNTRY. The company has a differentiated portfolio of small_molecule targeted oncology product candidates. Its lead pipeline programs are in potentially registrational clinical_trials for rare oncology indications : nirogacestat (gamma secretase inhibitor) is in a Phase_NUMBER clinical_trial for the treatment of desmoid tumors, and mirdametinib (MEK inhibitor) is in a Phase 2b clinical_trial for the treatment of neurofibromatosis type NUMBER patients_with plexiform neurofibromas (NF1 - PN). There_are DATE no therapies approved for either of these devastating CAUSE_OF_DEATH types. The company is also advancing several other programs addressing highly prevalent, genetically defined cancers.